Neuromorphic Edge-AI Investment Adviser

The mandate

The board keeps returning to one capital-allocation question: should it take a minority position and strategic licence in a neuromorphic processor venture for battery-powered rail condition sensors? Laboratory demonstrations show low-energy event detection, but directors cannot tell whether gains survive train vibration, temperature, sensor noise and sparse fault labels, or whether the required toolchain, foundry path and model conversion create dependence greater than the advantage.

The adviser will commit three working days each month to technical evidence review, chair counsel and management challenge, and attend four Vienna Investment Committee meetings. Quarterly Graz laboratory sessions and two diligence visits to Brno or Grenoble are included; written observations on a time-critical term sheet or test result are due within two European business days, with ad-hoc support capped at seven hours monthly.

The appointment runs for nine months from 1 February 2027. In month seven, the supervisory chair and committee chair will jointly assess independence and whether the investment decision has reached a durable gate; the full board may approve one extension of up to three months, but management cannot renew the mandate or vary its cadence through the proposed transaction.

The adviser has influence but no line authority, delegated investment power or executive responsibility. They cannot recommend securities to shareholders, approve the investment, direct laboratory tests, negotiate licence terms, select a foundry or speak for the company; management and the board remain accountable and must document where final judgements differ from the adviser’s challenged view.

The role may accompany two other significant mandates, but not a board seat with the target venture, its close competitor, a bidding edge-silicon supplier or a rail customer participating in the field trial. Equity, carried interest, research funding, patent interests and success fees connected to neuromorphic hardware, semiconductor fabrication or the advisers to the transaction require disclosure and may make appointment impossible.

Why the board wants this voice

The board understands rail electronics and conventional embedded processors but lacks experience carrying neuromorphic claims from benchmark demonstrations into a supportable industrial product. Engineering focuses on energy and latency, Corporate Development on access rights, and Finance on market scenarios without a shared technical-economic falsification plan. The chair wants a commercially literate technologist who can expose option value and dependency before enthusiasm becomes sunk cost.

What you will own

• Challenge whether event sparsity, latency, energy and accuracy advantages persist under representative vibration, temperature, noise, drift and rare-fault conditions.
• Test the benchmark against optimised conventional microcontroller, accelerator and duty-cycled alternatives using equivalent sensors, thresholds and system boundaries.
• Press management to include data conversion, model mapping, toolchain maturity, specialist labour, calibration and field-support burden in lifetime economics.
• Probe the target’s foundry, packaging, test, firmware and developer-tool dependencies for single points that could strand the investment or strategic licence.
• Shape staged investment gates linking capital release to reproducible silicon, field performance, supply assurance, intellectual-property access and customer evidence.
• Examine whether licence, source-access, escrow, change-control and continuity terms preserve product support if the venture pivots, fails or changes manufacturing partners.
• Frame the committee’s decision record across strategic upside, technical falsifiers, alternatives, follow-on capital, conflicts and the executive owner of each remaining risk.

Candidate qualifications

• Advised a board or investment committee on neuromorphic, event-driven or comparably novel edge-compute silicon beyond a research demonstration.
• Compared specialised silicon with strong conventional baselines under system-level energy, latency, accuracy, memory and integration constraints.
• Carried edge-AI hardware into harsh industrial, mobility or infrastructure environments where sensor drift and rare events changed laboratory conclusions.
• Evaluated foundry readiness, packaging, test yield, toolchain support and firmware capability as part of a deep-technology investment thesis.
• Structured technical and commercial gates for a minority investment or strategic licence and can evidence a decision altered by failed diligence.
• Managed conflicts involving venture holdings, semiconductor vendors, research institutions and transaction advisers while protecting confidential benchmark results.

Non-negotiables

• Can reserve three days monthly, attend all four Vienna meetings and complete the agreed Graz plus Brno or Grenoble diligence travel.
• Will disclose investments, board roles, carried interest, patents, funded research and supplier relationships across neuromorphic and edge-semiconductor markets.
• Accepts that the board alone decides the transaction and that the adviser may neither negotiate nor receive a success-linked payment.
• Has evaluated physical silicon and field evidence; papers, simulation or venture-screening experience without hardware diligence is insufficient.

1. 49 words maximum. Disclose every investment, board, patent, research or vendor relationship that could intersect this neuromorphic transaction.
2. 49 words maximum. Describe one specialised edge processor whose field evidence changed your investment view, including the conventional baseline used.
3. 49 words maximum. Confirm the Vienna, Graz and diligence-visit cadence and your response capacity during term-sheet or test-gate decisions.